Evaluation of the effectiveness of black seed oil in the treatment of vulvovaginal mucositis
Phase 3
Recruiting
- Conditions
- Inflammation of the vulvovaginal mucosa.Vaginitis, vulvitis and vulvovaginitis in diseases classified elsewhereN77.1
- Registration Number
- IRCT20200720048145N2
- Lead Sponsor
- Alborz University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Female
- Target Recruitment
- 100
Inclusion Criteria
Age 15-60 years
Do not using immunosuppressive drugs, antibiotics and topical creams and ointments during the last week
Do not be pregnant or breastfeeding
Normal Pap smear test
Exclusion Criteria
Allergy to the drug prescribed to the patient
Failure to follow treatment regularly and as directed
Mandatory administration of antibiotics by another physician outside the scope of the present study
Having sex with multiple partners during treatment
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie black seed oil's anti-inflammatory effects in vulvovaginal mucositis?
How does black seed oil compare to standard-of-care treatments like corticosteroids for vulvovaginal mucositis in phase III trials?
Are there specific biomarkers that correlate with improved outcomes in vulvovaginal mucositis patients treated with black seed oil?
What are the potential adverse events associated with topical black seed oil emulsions for vulvovaginal mucositis and how can they be managed?
What are the current combination therapies or competitor drugs for treating N77.1 vulvovaginal mucositis in clinical research?